Daily Trades
- Dylan Jovine
- Friday, October 13, 2023
The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
- Dylan Jovine
- Friday, October 6, 2023
Shares jumped 45% yesterday when Bloomberg News broke the story that "Sanofi is exploring acquisition of cancer drug maker Mirati."
- Dylan Jovine
- Thursday, December 15, 2022
I have an exciting recommendation for you this month: organ transplant firm, TransMedics (SYM: TMDX). It’s a bit outside of our normal focus on oncology and rare disease firms.
- Dylan Jovine
- Wednesday, September 21, 2022
Today I want to talk to you about KRAS mutations in cancer treatment. But first, we have three stocks to sell today. We’ll be taking profits on two and a loss on one.
- Dylan Jovine
- Tuesday, January 18, 2022
- Dylan Jovine
- Friday, October 16, 2020
- Dylan Jovine
- Friday, October 13, 2023
The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
- Dylan Jovine
- Friday, October 6, 2023
Shares jumped 45% yesterday when Bloomberg News broke the story that "Sanofi is exploring acquisition of cancer drug maker Mirati."
- Dylan Jovine
- Thursday, December 15, 2022
I have an exciting recommendation for you this month: organ transplant firm, TransMedics (SYM: TMDX). It’s a bit outside of our normal focus on oncology and rare disease firms.
- Dylan Jovine
- Wednesday, September 21, 2022
Today I want to talk to you about KRAS mutations in cancer treatment. But first, we have three stocks to sell today. We’ll be taking profits on two and a loss on one.
- Dylan Jovine
- Tuesday, January 18, 2022
- Dylan Jovine
- Friday, October 16, 2020
deal of the month
Categories
Dylan Jovine - "Uncovering the Game-Changing Drug of the Decade"
Protecting Your Financial Security from China's Attack on the US Dollar
Fed Rates Impacting Bonds: Explaining Maturity Length
Recent posts
Tags
Connect with Us
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.
